AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04102657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Left Arm Exercise
Description: Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the left arm. In the middle of the study, participants will switch to the right arm to complete their unilateral arm exercises.
Study NCT04102657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Right Arm Exercise
Description: Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the right arm. In the middle of the study, participants will switch to the left arm to complete their unilateral arm exercises.
Study NCT03480841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language ENhancement Assessment/intervention system
Description: The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.
Study NCT00996801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
Study NCT00996801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
Study NCT00996801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
Study NCT01722201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 mg tablet once a day
Study NCT00946517 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Parenting and behavioral questionnaires
Study NCT00996801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Description: Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
Study NCT00996801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Alendronate
Description: Placebo to alendronate once-weekly for 12 months
Study NCT04755972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation of N-acetylcysteine
Description: Group 1 will receive N-acetylcysteine inhalation every 12 hours from the beginning of invasive mechanical ventilation.
Study NCT03531307 — intervention group
Intervention type: OTHER
Intervention: Data correlation
Description: Correlation between lactate levels and Ki-67 index
Study NCT00484211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
Study NCT02045706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Worker Trainings
Study NCT03186833 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04755972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation of 5% sodium chloride
Description: Group 2 will receive inhalation with a 5% sodium chloride solution every 12 hours from the beginning of invasive mechanical ventilation.
Study NCT04755972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation of 8,4% sodium bicarbonate
Description: Group 3 will receive inhalation of 8.4% sodium bicarbonate every 12 hours from the beginning of invasive mechanical ventilation.
Study NCT02327442 — intervention group
Intervention type: RADIATION
Intervention: 68Ga-NOTA-NFB
Description: In this investigation, 68Ga-NOTA-NFB is employed to a preclinical trial, including radiation dosimetry study in healthy volunteers and the first application in glioma patients, to assess the safety, dosimetry property and evaluate the CXCR4 expression in glioma patients and breast cancer patients.
Study NCT04057261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide Pen Injector [Victoza]
Description: Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen
Study NCT04057261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo once daily, subcutaneous injection via pre-filled pen.
Study NCT02281266 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: curative resection
Study NCT02281266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curative resection
Study NCT02281266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thymalfasin
Description: 1.6mg twice a week, 12 months
Study NCT00996801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Alendronate
Description: Placebo to alendronate once-weekly for 12 months
Study NCT04229212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)
Description: In the drained group, a hemovac drain (Zimmer Biomet, Autotransfusion System \[HAS\], United State) was placed beneath the fascia of the gluteus muscle, surrounding the entry point of the nail at the fracture site.
Study NCT02281266 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: nucleoside analog (suggest to use entecavir)
Study NCT04332614 — intervention group
Intervention type: BEHAVIORAL
Intervention: Less-is-better
Description: Email
Study NCT02281266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nucleoside analog (suggest to use entecavir)
Study NCT03987074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly
Study NCT03899142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a human hepatitis B immunoglobulin solution for injection for intramuscular administration
Description: intramuscular administration
Study NCT04332614 — intervention group
Intervention type: BEHAVIORAL
Intervention: Social proof
Description: Email
Study NCT04332614 — intervention group
Intervention type: BEHAVIORAL
Intervention: Endowment / decision staging
Description: Email
Study NCT04332614 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standard email
Description: Email
Study NCT03602885 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual chemotherapy education (CE)
Description: Standard chemo education will given per hospital guideline
Study NCT03602885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chemotherapy education intervention (CEI)
Description: Video, booklet, and website educational materials
Study NCT04690920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
Study NCT04690920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
Study NCT02838901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beet it Beetroot juice
Description: Concentrated organic beetroot (98%) and lemon juice (2%); 70ml bottle
Study NCT02838901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beet It Placebo Beetroot juice
Description: Concentrated organic beetroot (98%) and lemon juice (2%) with nitrate extracted; 70ml bottle. Beet It Placebo Beetroot juice.
Study NCT04616209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor-derived NK cell infusion
Description: PB103 administrations will be separated by 4-week interval
Study NCT00823212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROMUS Coronary Stent System
Description: PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
Study NCT00823212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element Coronary Stent System
Description: PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS \[XIENCE V\] stent).
Study NCT00823212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
Study NCT00823212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
Study NCT00823212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thienopyridine
Description: Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
Study NCT00823212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thienopyridine
Description: Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
Study NCT02875223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: Specified dose on specified days
Study NCT02922842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Study NCT02922842 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Study NCT00149994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Study NCT00149994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study NCT00149994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
Study NCT00149994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
Study NCT00149994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
Study NCT00149994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
Study NCT00149994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
Study NCT00149994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
Study NCT04394273 — intervention group
Intervention type: OTHER
Intervention: Exercise
Description: stabilization exercise
Study NCT02069990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Study NCT02069990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Study NCT02875223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Specified dose on specified days
Study NCT02875223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days
Study NCT03782051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined phacoemulsification and viscocanalostomy
Description: phacoemulsification with viscocanalostomy
Study NCT03782051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined phacoemulsification and viscocanalostomy and ologen
Description: phacoemulsification with viscocanalostomy with ologen
Study NCT04375189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Risk Clinic
Description: Subgroup of primary care clinic where patients have longer time slots, supervision by one longitudinal attending, bedside presentations
Study NCT04320381 — intervention group
Intervention type: BEHAVIORAL
Intervention: Qualitative Interview
Description: 2 Semi-Structured Qualitative Interviews
Study NCT01229059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Lipovenös lipid infusion
Description: Lipid enriched infusions will be applied for 2-6 hours.
Study NCT00830843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol(3-4 mg/kg/ora)administrated for 2 hours.
Study NCT00830843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
Study NCT00708643 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Silicone Hydrogel Contact Lens
Description: contact lens
Study NCT00708643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A
Description: contact lens
Study NCT04345263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTA pulpotomy
Description: Cutting the coronal portion of the pulp to the level of canal orifices and applying the dressing and restoration
Study NCT01870440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex Intravitreal Injection (0.7 mg)
Description: Intravitreal Injection
Study NCT03366441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone call
Description: From 20 October to 10 November 2016, telephone calls were given to the donors in the phone call group
Study NCT03366441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS
Description: Text messages were sent to an equal number of donors in the SMS group
Study NCT02047734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Oral capsule, daily for 24 months
Study NCT02047734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozanimod placebo
Description: Oral capsule, daily for 24 months
Study NCT02047734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Intramuscular injection, 30 µg, weekly for 24 months
Study NCT02047734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a placebo
Description: Intramuscular injection, weekly for 24 months
Study NCT02693860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huJ591
Description: Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute.
Study NCT02693860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-J591
Description: Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO-huJ591 with 89Zr is achieved by the addition of 89Zr-oxalate to the DFO-huJ591 in ammonium acetate buffer.
Study NCT03739047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Desensitization with flipped spoon
Description: Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by desensitization. Desensitization will be conducted for 3, 45-minute treatment meals. Puree will be presented on a flipped EZ spoon after the desensitization sessions are completed. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
Study NCT03739047 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: flipped spoon
Description: Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by puree being presented from a flipped EZ spoon. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
Study NCT05497791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial laser stimulation associated with NMES
Description: The cluster was applied on the skin covering the head. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.~The NMES was started, after 5 minutes the transcranial laser stimulation (active or placebo-treatment) was started. Then, the therapies were combined. After finishing the transcranial laser stimulation (active or placebo-treatment), the NMES was continued until completing 30 minutes.
Study NCT05497791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The transcranial laser was applied identically for all groups, but the null dose was used in the placebo group. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.
Study NCT02572414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promotion Intervention
Description: Men Together Making a Difference Health Promotion Intervention, which included three, 3-hour weekly sessions, implemented in small groups by trained facilitators using scripted manuals, was designed to increase self-efficacy, outcome expectancy, and skills for behaviors tied to cardiovascular disease, diabetes, hypertension, and cancer. It encouraged men to adhere to guidelines for physical activity, 5-a-Day diet, and colon cancer screening. It encouraged at least 30 min of moderate-intensity aerobic activity on 5 days or at least 20 min of vigorous-intensity aerobic activity on 4 days and muscle-strengthening activity on at least 2 days each week. Participants identified their personal barriers to engaging in the recommended behaviors and strategies for surmounting those barriers.
Study NCT02572414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Awareness Control Intervention
Description: Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
Study NCT04684043 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: PCI was performed using drug-eluting stents
Study NCT02842073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Standard clinical doses of naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
Study NCT02842073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
Study NCT00493896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: The dose for Arixtra is 2.5 mg once daily, subcutaneously.
Study NCT00493896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: The dose for Lovenox is 40 mg once daily, subcutaneously.
Study NCT01645787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-aminopyridine
Description: 10 mg/twice daily